

侵襲性髄膜炎菌感染症と髄膜炎菌ワクチンについての情報提供

侵襲性髄膜炎菌感染症は髄膜炎菌を原因とする重大な感染症です。髄膜炎菌は一部の健康な人の鼻咽頭の粘膜に常在しています（無症状保菌者は 0.0～0.4%存在すると言われています）。菌が感受性のある人に感染すると、風邪とまぎらわしい症状が生じて、短時間のうちに激しい頭痛、嘔吐、意識障害やけいれん発作が現れ、高い確率で死に至る（あるいは重大な脳の後遺症を残す）、重篤な転機をとります。好発年齢は乳幼児・10 代後半・高齢者とされ、人と人との接触が密な場所で発生しやすいため、多くの人が長い時間を一緒に過ごす学生寮はハイリスクとなります。実際に日本でも、高校や大学の寮での集団発生や死亡例が発生しています。

予防には「髄膜炎菌ワクチン」が有効です。接種は任意となりますが、ご検討ください。

商品名	〈国内承認済みワクチン〉 メンクアッドフィ。 〈輸入ワクチン〉 Menveo [®] 、Bexsero [®] 、Trumenba [®]
接種回数	1 回：メンクアッドフィ。Menveo [®] 2 回：Bexsero [®] 3 回：Trumenba [®]
費用	1 回 19,000 円～25,000 円（施設によって異なる）
効果	およそ 80～95% 接種から 5 年経つと効果は失われるため、5 年毎の接種が必要。
相談 接種可能医療機関	◆東京科学大学病院 感染症内科 本学病院で接種ご希望の方は、まずは保健管理センターへお問い合わせください。 ◆トラベルクリニックリスト （日本渡航医学会） ◆髄膜炎菌について相談できる 医療機関検索 （サノフィ株式会社） ◆予防接種実機機関検索 （厚生労働省検疫所）   

本件問い合わせ先

（理工学系）大岡山保健管理センター hokenkanri@jim.titech.ac.jp

（医歯学系）湯島保健管理センター soudan.hsc@tmd.ac.jp




From: Director of the Student Healthcare Center

Information about invasive meningococcal disease (IMD) and the meningococcal vaccine

Invasive meningococcal disease (IMD) is a serious infectious disease caused by the bacteria *Neisseria meningitidis* (*N. meningitidis*). Healthy individuals can carry the bacteria in the mucous membranes of their nose and throat; up to 0.4% of people may be asymptomatic carriers of *N. meningitidis*. When a susceptible individual is infected, they may experience symptoms that resemble those of a common cold. However, the disease can progress rapidly, causing severe headaches, vomiting, altered mental states, or convulsive seizures. Infected individuals face a high risk of death, brain damage, or other serious and permanent complications.

Disease incidence rates are highest among infants and young children, adolescents 15 to 19 years of age, and older adults. Since outbreaks tend to occur in places where individuals are often in close quarters for extended periods, students living in dormitories are also considered to be at high risk of developing IMD. In Japan, there have been outbreaks at high school and university dormitories, and some cases were fatal.

Meningococcal vaccines are effective to prevent the disease. IMD vaccination is voluntary, but you are encouraged consider getting vaccinated.

Vaccines	(Approved for domestic distribution) MenQuadfi® (Imported vaccines) Menveo®, Bexsero®, Trumenba®
Required number of injections	Single dose : MenQuadfi®, Menveo® Two doses: Bexsero® Three doses: Trumenba®
Cost	JPY 19,000 to 25,000 (depending on the healthcare facility)
Effectiveness	Around 80-95% Note that effectiveness fades after 5 years, so a booster vaccination is needed to maintain this protection.
Resources Facilities that can provide vaccinations (only in Japanese)	<ul style="list-style-type: none"> ◆ Science Tokyo Hospital Infectious Diseases Contact the Student Healthcare Center for details. ◆ “Travel Clinic List” on the Japanese Society of Travel and Health (JSTH) website.(QR Code ①) ◆ Find healthcare facilities available for consultation, searchable by region, on the Sanofi website for information about IMD (QR Code ②) ◆ Search for healthcare facilities that can provide vaccinations on the “Quarantine Information Office (FORTH)” website operated by the Ministry of Health, Labour, and Welfare of Japan(QR Code ③) <div style="display: flex; justify-content: space-around; align-items: center; margin-top: 10px;">    </div> <div style="display: flex; justify-content: space-around; align-items: center; margin-top: 5px;"> ① ② ③ </div>

For inquiries about this notice: Student Healthcare Center

【Science and Engineering】 info_health@shc.isct.ac.jp

【Dental and Medical】 soudan.hsc@tmd.ac.jp